Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

NCT ID: NCT01273909

Last Updated: 2014-06-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this prospective, observational study is to investigate the clinical, psychosocial, and patient satisfaction outcomes of patients who undergo perforator flap reconstruction for breast reconstruction and/or vascularized lymph node transfer (VLNTx) for the treatment of lymphedema.

The investigators hypothesize that (1) perforator flap breast reconstruction will result in excellent clinical, psychosocial, and patient satisfaction outcomes compared to non-perforator flap breast reconstruction; (2) perforator flap breast reconstruction is associated with less persistent postsurgical pain than other forms of breast reconstruction, even after controlling for major cofactors, such as the extent of auxiliary lymph node dissection and the use of radiation therapy; (3) perforator flap reconstruction for the treatment of Lymphedema (i.e., VLNTx ) will result in the reduction of symptoms and complications of lymphedema.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer is a serious health issue that affects 1 in 8 women. Although numerous treatments have arisen in recent years to aggressively combat this disease and increase survivorship, many survivors develop a crippling condition that can result in devastating physical and psychological impairments. Breast reconstruction by any method may help recovery psychologically. However, some individuals still report experiencing pain following their recovery from surgery. Additionally, secondary lymphedema is a common yet poorly understood complication of breast cancer patients. For those individuals who undergo axillary lymph node dissection the rates of incidence of lymphedema approach 47%. These rates tend to increase further for patients who receive irradiation treatment or mastectomies. Currently there is no known cure for lymphedema. Current treatments include non-invasive measures as well as surgical interventions. Vascularized lymph node transfer (VLNTx) is a fairly recent surgical procedure that has shown promising results.

The goal of this research study is to analyze the clinical outcome of subjects who undergo breast reconstruction with perforator flaps and/or VLNTx using information collected as part of standard care.

Clinical data will be collected prospectively. All subjects who undergo a surgical procedure will complete the online persistent postsurgical pain assessment questionnaire.

The BreastQ questionnaire will be completed by patients prior to and after undergoing breast reconstruction and/or lymphedema treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Hereditary Breast/Ovarian Cancer (brca1, brca2) Acquired Lymphedema Congenital Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perforator Flap Breast Reconstruction

Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer

Perforator Flap Breast Reconstruction

Intervention Type PROCEDURE

perforator flap breast reconstruction with or without vascularized lymph node transfer

Vascularized Lymph Node Transfer

Intervention Type PROCEDURE

perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction

Vascularized Lymph Node Transfer

Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction

Perforator Flap Breast Reconstruction

Intervention Type PROCEDURE

perforator flap breast reconstruction with or without vascularized lymph node transfer

Vascularized Lymph Node Transfer

Intervention Type PROCEDURE

perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Perforator Flap Breast Reconstruction

perforator flap breast reconstruction with or without vascularized lymph node transfer

Intervention Type PROCEDURE

Vascularized Lymph Node Transfer

perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DIEP Flap SGAP Flap IGAP Flap SIEA Flap TUG Flap TDAP Flap ICP Flap VLNTx

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Undergoing perforator flap surgery for breast reconstruction and/or vascularized lymph node transfer for treatment of lymphedema

Exclusion Criteria

* Pregnant
* unable to read
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The DrMarga Practice Group

UNKNOWN

Sponsor Role collaborator

The Center for Restorative Breast Surgery, LLC

OTHER

Sponsor Role collaborator

The National Institute of Lymphology

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marga F. Massey, M.D.

Principle Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marga F. Massey, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Institute of Lymphology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institute of Lymphology

Chicago, Illinois, United States

Site Status

The Center for Restorative Breast Surgery

New Orleans, Louisiana, United States

Site Status

The DrMarga Practice Group

Charleston, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Massey MF, Spiegel AJ, Levine JL, Craigie JE, Kline RM, Khoobehi K, Erhard H, Greenspun DT, Allen RJ Jr, Allen RJ Sr; Group for the Advancement of Breast Reconstruction. Perforator flaps: recent experience, current trends, and future directions based on 3974 microsurgical breast reconstructions. Plast Reconstr Surg. 2009 Sep;124(3):737-751. doi: 10.1097/PRS.0b013e3181b17a56.

Reference Type BACKGROUND
PMID: 19730293 (View on PubMed)

Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985-92. doi: 10.1001/jama.2009.1568.

Reference Type BACKGROUND
PMID: 19903919 (View on PubMed)

Dayangac M, Makay O, Yeniay L, Aynaci M, Kapkac M, Yilmaz R. Precipitating factors for lymphedema following surgical treatment of breast cancer: implications for patients undergoing axillary lymph node dissection. Breast J. 2009 Mar-Apr;15(2):210-1. doi: 10.1111/j.1524-4741.2009.00703.x. No abstract available.

Reference Type BACKGROUND
PMID: 19292814 (View on PubMed)

Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006 Mar;243(3):313-5. doi: 10.1097/01.sla.0000201258.10304.16.

Reference Type BACKGROUND
PMID: 16495693 (View on PubMed)

Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147-54. doi: 10.1196/annals.1413.014.

Reference Type BACKGROUND
PMID: 18519968 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1116697

Identifier Type: OTHER

Identifier Source: secondary_id

MFM001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ILR to Prevent BRCL_MCC 23608
NCT07127003 NOT_YET_RECRUITING NA
Lymphovenous Anastomosis for Breast Cancer Lymphedema
NCT06302361 ACTIVE_NOT_RECRUITING NA
Can ILR Reduce the Risk of Arm Lymphedema?
NCT05742945 ACTIVE_NOT_RECRUITING NA
Subclinical Lymphedema Treatment Study
NCT03292198 ACTIVE_NOT_RECRUITING NA
Lymphedema Surveillance Study
NCT02743858 RECRUITING